KRAS and neoplasm: Oncogenic KRAS mutations engage in various metabolism pathways in tumors, including lipometabolism, glycometabolism, amino acid metabolism, and nucleotide metabolism, to meet the high biosynthetic demands of proliferating tumor cells and accelerate their growth [17, 18].